Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia

Leukemia

Volumn 21, Issue 1, 2007, Pages 93-101

  Pocaly, M ^a   Lagarde, V ^a   Etienne, G ^a   Ribeil, J A ^b   Claverol, S ^c   Bonneu, M ^c   Moreau Gaudry, F ^a   Guyonnet Duperat, V ^a   Hermine, O ^b   Melo, J V ^d   Dupouy, M ^a   Turcq, B ^a   Mahon, F X ^a   Pasquet, J M ^a  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK TRANSCRIPTION FACTOR 1; IMATINIB; NILOTINIB; RNA;

ARTICLE; BLAST CELL; CANCER PATIENT; CELL DEATH; CELL STRAIN K 562; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL;

EID: 33845525384     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404463     Document Type: Article

References (45)

1. Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 1993; 82: 3524-3529.
2. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
3. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
4. Goldman JM. Chronic myeloid leukemia - still a few questions. Exp Hematol 2004; 32: 2-10.
5. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
6. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-3698.
7. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
8. Deininger MW, Druker BJ. SRCircumventing imatinib resistance. Cancer Cell 2004; 6: 108-110.
9. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002; 99: 3530-3539.
10. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
11. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
12. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004; 3: 1001-1010.
13. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
14. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
15. Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641-1650.
16. Larghero J, Leguay T, Mourah S, Madelaine-Chambrin I, Taksin A-L, Raffoux E et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec(R)) in vitro and in vivo. Biochem Pharmacol 2003; 66: 1907-1913.
17. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373.
18. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-1079.
19. Nollen EAA, Morimoto RI. Chaperoning signaling pathways: Molecular chaperones as stress-sensing 'heat shock' proteins. J Cell Sci 2002; 115: 2809-2816.
20. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003; 228: 111-133.
21. Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 2005; 105: 1246-1255.
22. Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A, Kroemer G. HSP27 and HSP70: Potentially oncogenic apoptosis inhibitors. Cell Cycle 2003; 2: 579-584.
23. Beere HM. 'The stress of dying': The role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004; 117: 2641-2651.
24. Sreedhar AS, Csermely P. Heat shock proteins in the regulation of apoptosis: New strategies iA tumor therapy: a comprehensive review. Pharmacol Ther 2004; 101: 227-257.
25. Luders J, Demand J, Hohfeld J. The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome. J Biol Chem 2000; 275: 4613-4617.
26. Demand J, Alberti S, Patterson C, Hohfeld J. Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr Biol 2001; 11: 1569-1577.
27. Hu W, Wu W, Verschraegen CF, Chen L, Mao L, Yeung SC et al. Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics 2003; 3: 1904-1911.
28. Ray S, Lu Y, Kaufmann SH, Gustafson WC, Karp JE, Boldogh I et al. Genomic mechanisms of p210BCR-ABL signaling: Induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. J Biol Chem 2004; 279: 35604-35615.
29. Barthe C, Gharbi MJ, Lagarde V, Chollet C, Cony-Makhoul P, Reiffers J et al. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br J Haematol 2002; 119: 109-111.
30. Joubert-Caron R, Feuillard J, Kohanna S, Poirier F, Le Caer JP, Schuhmacher M et al. A computer-assisted two-dimensional gel electrophoresis approach for studying the variations in protein expression related to an induced functional repression of NFkappaB in lymphoblastoid cell lines. Electrophoresis 1999; 20: 1017-1026.
31. Smith DL, Evans CA, Pierce A, Gaskell SJ, Whetton AD. Changes in the proteome associated with the action of Bcr-Abl tyrosine kinase are not related to transcriptional regulation. Mol Cell Proteomics 2002; 1: 876-884.
32. Pasquet JM, Quek L, Pasquet S, Poole A, Matthews JR, Lowell C et al. Evidence of a role for SHP-1 in platelet activation by the collagen receptor glycoprotein VI. J Biol Chem 2000; 275: 28526-28531.
33. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-2653.
34. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
35. Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163.
36. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
37. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T et al. Molecular characterization and sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-Allylamino-17-demethoxygeldanamycin. Cancer Res 2002; 62: 5761-5769.
38. Morimoto RI. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev 1998; 12: 3788-3796.
39. Pirkkala L, Nykanen P, Sistonen L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J 2001; 15: 1118-1131.
40. Shi Y, Mosser DD, Morimoto RI. Molecular chaperones as HSF1-specific transcriptional repressors. Genes Dev 1998; 12: 654-666.
41. Xing H, Wilkerson DC, Mayhew CN, Lubert EJ, Skaggs HS, Goodson ML et al. Mechanism of hsp70i gene bookmarking. Science 2005; 307: 421-423.
42. Sistonen L, Sarge KD, Phillips B, Abravaya K, Morimoto RI. Activation of heat shock factor 2 during hemin-induced differentiation of human erythroleukemia cells. Mol Cell Biol 1992; 12: 4104-4111.
43. He H, Soncin F, Grammatikakis N, Li Y, Siganou A, Gong J et al. Elevated expression of heat shock factor (HSF) 2A stimulates HSF1-induced transcription during stress. J Biol Chem 2003; 278: 35465-35475.
44. Garrido C, Gurbuxani S, Ravagnan L, Kroemer G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun 2001; 286: 433-442.
45. Gabai VL, Budagova KR, Sherman MY. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene 2005; 24: 3328-3338.